Finzati - Logo
AUPH logo

Aurinia Pharmaceuticals Inc.

AUPH • Biotechnology
$16.08
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$2.15B
Growth
1.0%
Cash Flow
2/5
Trend
Volatile
Evidence
Stable or improving margins · 101.5%Positive revenue growth · 56.4%Positive free cash flow · 1.01Reasonable earnings multiple · 7.46Manageable debt level · 0.13
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:00 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$16.08
Change0.00%
Shares Out133.53M
Market Cap$2.15B
Enterprise Value$1.70B
52W Range10.34 - 19.25
Beta1.42
P/E6.84
P/S6.89
P/B3.49
P/FCF10.40
EV/Sales5.47

Investment DNA

How strong this company looks for long-term investors

82
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
95/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
70/100
Why this score▼
Stable or improving margins · 101.5%Positive revenue growth · 56.4%Positive free cash flow · 1.01Reasonable earnings multiple · 7.46Manageable debt level · 0.13Healthy liquidity · 5.25

Analyst view

Analyst sentiment and price target

AUPH
Analyst sentiment
Based on 15 analyst votes · 2026-09-05
87/100
Bullish
Bullish
11
Hold
4
Bearish
0
Price Target
2026-08-07
Low
$6.00
Mean
$12.60
Median
$13.00
High
$16.00

Company Overview

IPO: 9/3/2014
Industry: Biotechnology
P/B i: 3.49
Debt / Equity i: 0.13
Operating Margin: 37.06%
Net Margin: 1.01%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.13
Current Ratio: 5.25
Quick Ratio: 4.76
Status: Strong

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected
Bailey Jeffrey Allen
Transaction: 06/04/2026
BUY
Change
+23,931
Price
$15.67
Filing
06/08/2026
Type
BUY
Nova Tina Susan
Transaction: 06/04/2026
BUY
Change
+23,931
Price
$15.67
Filing
06/08/2026
Type
BUY
Goetz Kathleen
Transaction: 06/04/2026
BUY
Change
+23,931
Price
$15.67
Filing
06/08/2026
Type
BUY